RZLT Rezolute Inc
Company Analysis
Latest News
🔴 Rezolute is trading 7.2% down today as biotech weakness may contribute
Rezolute is trading 7.18% down at $3.62 after several consecutive sessions of declines, with biotech-sector weakness potentially contributing. - No clear...
🔴 Rezolute is trading 5% down with no clear catalyst identified
Rezolute is trading 5.08% down now at $4.01, with no reliable report linking the decline to a new company event. - The price context shows a further decline...
Rezolute Completes Phase 3 Enrollment for Tumor Hyperinsulinism Drug, Topline Data Expected Dec 2026
Rezolute, Inc. announced it has completed patient enrollment for its pivotal Phase 3 registrational study, upLIFT, evaluating its drug candidate ersodetug for...
🟢 Rezolute is trading 6.6% up in after-hours trading after announcing full Phase 3 upLIFT enrollment
Rezolute is trading at $4.51, up 6.62%, after-hours following its announcement that the Phase 3 upLIFT study of ersodetug is fully enrolled. - The company...
🔴 Rezolute is trading 5% down on October 14, 2026, with no clear company-specific catalyst identified
Rezolute is trading at $4.37 (-5.21%) in live trading, with broader risk-off pressure a possible backdrop—not an established cause. - No new Rezolute...
🔴 Rezolute is trading 5% down
Rezolute is trading 5.24% down at $4.62, with no clear company-specific announcement identified to explain the October 13 decline. - Biotech was down 2.01%,...
🟢 Rezolute is trading 5% up today
Rezolute is trading at $4.89 (+5.38%) on October 9, amid biotech-sector strength; no direct cause of the move was confirmed. - XBI was reported up 2.50% during...
🟢 Rezolute is trading 5% up today
Rezolute is trading at $4.61, up 5.25% in live trading on October 8, 2026; no clear company-specific catalyst has been identified. - Rezolute’s...
🔴 Rezolute is trading 10% down in pre-market
Rezolute is trading 10.09% lower at $3.94 in pre-market, with no clearly reported company-specific announcement on October 8, 2026, explaining the decline. -...
🟢 Rezolute is trading 5% up today after FDA recommended an ersodetug pre-BLA meeting
Rezolute is trading 5.21% up at $4.54 after the FDA recommended that the company request a pre-BLA meeting for ersodetug. - The recommendation followed the...
🟢 Rezolute is trading 7% up in pre-market after FDA recommended a pre-BLA meeting
Rezolute is trading at $4.63, up 6.99% in pre-market after the FDA recommended a pre-BLA meeting for ersodetug on October 5, following its review of sunRIZE...
Rezolute's FDA Pre-BLA Nod Sends Shares Soaring, But Can a Failed Trial Really Lead to an Approval?
Shares of Rezolute surged 11% to $4.45 after the FDA took the unusual step of recommending a pre-BLA meeting — essentially an invitation to discuss filing for...
🟢 Rezolute is trading 11% up today after FDA recommended pre-BLA meeting for ersodetug
Rezolute is trading 10.99% up at $4.45 after the FDA recommended a pre-BLA meeting for ersodetug. - The October 5, 2026, gain followed the recommendation,...
🟢 Rezolute is trading 5% up today after FDA recommended a pre-BLA meeting for ersodetug
Rezolute is trading at $4.22, up 5.24%, with the FDA’s pre-BLA meeting recommendation for ersodetug the clearest explanation for the gain. - On October 5,...
FDA Recommends Pre-BLA Meeting for Rezolute's Congenital HI Drug Ersodetug
Rezolute, Inc. announced that the U.S. Food and Drug Administration (FDA) has recommended the company request a pre-BLA (Biologics License Application) meeting...
🟢 Rezolute is trading 13.72% up in pre-market with no clear catalyst identified
Rezolute is trading at $4.56, up +13.72% in pre-market, with no clear catalyst established. - No fresh company announcement explaining the October 5...
🟢 Rezolute is trading 8.7% up in pre-market
Rezolute is trading at $4.50, up 8.70% in pre-market, with no confirmed catalyst identified. - Craig-Hallum upgraded Rezolute to Buy on September 29 and...
🟢 Rezolute is trading 5.8% up today without a fresh company announcement
Rezolute is trading 5.8% up at $4.33 on September 30, 2026; no fresh company announcement surfaced to explain the move. - On September 29, Craig-Hallum...
🟢 Rezolute is trading 7% up today amid Craig-Hallum's reported Buy upgrade
Rezolute is trading at $4.47, up 7.06%, with a same-day analyst upgrade a plausible catalyst. - The supplied live price context is timestamped 9:34 a.m. EST on...
Craig-Hallum's Buy Call on Rezolute Implies 56% Upside — But Can a Single Drug Trial Justify That Bet?
Shares of Rezolute Inc. surged 7.7% in pre-market trading to $4.50 on September 29 after Craig-Hallum reportedly upgraded the stock to Buy and slapped a $7...